Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Top Cited Papers
Open Access
- 28 June 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 18 (7), 865-875
- https://doi.org/10.1634/theoncologist.2013-0095
Abstract
The discovery of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) has stimulated renewed interest in oncogenic fusions as potential therapeutic targets. Recently, genetic alterations in ROS1 and RET were identified in patients with NSCLC. Like ALK, genetic alterations in ROS1 and RET involve chromosomal rearrangements that result in the formation of chimeric fusion kinases capable of oncogenic transformation. Notably, ROS1 and RET rearrangements are rarely found with other genetic alterations, such as EGFR, KRAS, or ALK. This finding suggests that both ROS1 and RET are independent oncogenic drivers that may be viable therapeutic targets. In initial screening studies, ROS1 and RET rearrangements were identified at similar frequencies (approximately 1%–2%), using a variety of genotyping techniques. Importantly, patients with either ROS1 or RET rearrangements appear to have unique clinical and pathologic features that may facilitate identification and enrichment strategies. These features may in turn expedite enrollment in clinical trials evaluating genotype-directed therapies in these rare patient populations. In this review, we summarize the molecular biology, clinical features, detection, and targeting of ROS1 and RET rearrangements in NSCLC.Keywords
Funding Information
- U.S. National Institutes of Health (5R01CA164273-02)
- V Foundation Translational Research Grant
This publication has 95 references indexed in Scilit:
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancerCancer Medicine, 2012
- Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokersCell Research, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2009
- The impact of translocations and gene fusions on cancer causationNature Reviews Cancer, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004